---
reference_id: "PMID:12894379"
title: Current disease-modifying therapies in multiple sclerosis.
authors:
- Kieseier BC
- Hartung HP
journal: Semin Neurol
year: '2003'
doi: 10.1055/s-2003-41138
content_type: abstract_only
---

# Current disease-modifying therapies in multiple sclerosis.
**Authors:** Kieseier BC, Hartung HP
**Journal:** Semin Neurol (2003)
**DOI:** [10.1055/s-2003-41138](https://doi.org/10.1055/s-2003-41138)

## Content

1. Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138.

Current disease-modifying therapies in multiple sclerosis.

Kieseier BC(1), Hartung HP.

Author information:
(1)Department of Neurology, Heinrich-Heine-University, Moorenstrasse 5, 40225 
DÃ¼sseldorf, Germany.

Erratum in
    Semin Neurol. 2003 Sep;23(3):343.

In recent years, the usefulness of interferon beta and glatiramer acetate in the 
treatment of relapsing-remitting multiple sclerosis (RRMS) has been established. 
Interferon beta has also been shown to be efficacious in secondary-progressive 
multiple sclerosis (SPMS) as well as in patients with isolated syndromes at risk 
to develop clinically definite multiple sclerosis (MS). Mitoxantrone is another 
disease-modifying drug that is available for SPMS and severe cases of RRMS. The 
clinical utility of disease-modifying agents in MS will be reviewed with respect 
to the anti-inflammatory, immunomodulatory, and immunosuppressive treatments 
that are currently available. Symptomatic therapies will not be considered.

DOI: 10.1055/s-2003-41138
PMID: 12894379 [Indexed for MEDLINE]